Furthermore, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was also found to ameliorate pulmonary fibrosis via targeting ferroptosis.[78] Interestingly, in the bleomycin-induced mouse model, the pulmonary fibrosis could be ameliorated by DFO via transbronchial injection rather than oral administration or intraperitoneal injection,[84] indicating that the route of administration should be considered when employing ferroptosis as a therapeutic target. The gene discussed is SLC5A2; the disease is pulmonary fibrosis.